Michigan HIE goes live on NwHIN

The South East Michigan Health Information Exchange (SEMHIE) has been validated for conformance and interoperability testing by the Office of the National Coordinator for Health IT (ONC) and is now live on the Nationwide Health Information Network Exchange (NwHIN).

The Ann Arbor, Mich.-based organization joined a 20-member group of federal agencies and non-federal partners authorized to operate on NwHIN.

SEMHIE developed its HIE under a $2.9 million contract with the U.S. Social Security Administration (SSA). The contract provides for the authorized exchange of summary patient information for disability determination between SEMHIE health systems’ and providers’ EMR systems and the SSA.

When complete, SSA expects to reduce the average wait across the U.S. for eligibility determination from 457 days to one to two weeks and the delivery of medical information from providers to the SSA to five hours, SEMHIE stated.

Funds from this contract award are enabling two major hospital systems that are collaborative partner members of SEMHIE—Henry Ford Health System and Oakwood Healthcare System—to exchange authorized summary patient records for disability determination with the SSA in standard continuity of care document format, linking their systems to the NwHIN and meeting meaningful use criteria.

At the conclusion of this SSA contract, the HIE anticipates that other major hospital systems and providers in the Detroit metro area and across Michigan will use the SEMHIE’s infrastructure and services for disability claims processing.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.